DBV Technologies S.A. (DBVT)
DBV Technologies S.A. (DBVT) Stock Price, Analysis & Data
| Bid | 14.11 |
| Market Cap | 897.12M |
| Revenue (ttm) | 5.04M |
| Net Income (ttm) | -175.95M |
| Beta | -0.24 |
| EPS (ttm) | -3.5 |
| PE Ratio (ttm) | n/a |
| Forward PE | -26.86 |
| P/B (ttm) | 5.27 |
| P/S (ttm) | 178.14 |
| Earnings Date | Oct 28, 2026 |
| Ask | 14.11 |
| Volume | 77,538 |
| Avg. Volume (20D) | 316,314 |
| Open | 14.12 |
| Previous Close | 14.09 |
| Day's Range | 14.12 - 14.39 |
| 52-Week Range | 8.70 - 26.18 |
| Analyst | n/a |
| Price Target | 46.9 (228.43%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DBVT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy ...
Financial Performance
In 2025, DBV S.A.'s revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -146.95M, an increase of 28.99%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for DBVT stock is "null". The 12-month stock price forecast is 46.9, which is upside of 228.43% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade